Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Amicus Therapeutics Inc. shares valued at $117,052 were sold by Crowley John F on Nov 01. At $10.32 per share, Crowley John F sold 11,346 shares. The insider’s holdings dropped to 823,737 shares worth approximately $8.32 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
Also, Campbell Bradley L sold 5,470 shares, netting a total of over 54,759 in proceeds. Following the sale of shares at $10.01 each, the insider now holds 689,618 shares.
Before that, Crowley John F had sold 10,468 shares from its account. In a trade valued at $114,148, the Executive Chairman traded Amicus Therapeutics Inc. shares for $10.90 each. Upon closing the transaction, the insider’s holdings decreased to 10,468 shares, worth approximately $8.43 million.
As published in their initiating research note from Morgan Stanley on September 09, 2022, Amicus Therapeutics Inc. [FOLD] has been an Equal-weight and the price target has been revised to $14. This represents a 27.86% premium over Thursday’s closing price. As of January 14, 2022, SVB Leerink has increased its “Mkt perform” rating to a “an Outperform” for FOLD. Earlier on November 15, 2021, Stifel upgraded its rating. Their new recommendation was “a Buy” for FOLD stock which previously was a “a Hold”.
Analyzing FOLD Stock Performance
On Thursday, Amicus Therapeutics Inc. [NASDAQ: FOLD] rose 1.10% to $10.10. The stock’s lowest price that day was $9.85, but it reached a high of $10.29 in the same session. During the last five days, there has been a drop of approximately -2.70%. Over the course of the year, Amicus Therapeutics Inc. shares have dropped approximately -12.55%. Shares of the company reached a 52-week high of $12.96 on 08/25/22 and a 52-week low of $5.91 on 05/09/22. A 50-day SMA is recorded $10.79, while a 200-day SMA reached $9.66. Nevertheless, trading volume fell to 1.64 million shares from 1.96 million shares the previous day.
Support And Resistance Levels for Amicus Therapeutics Inc. (FOLD)
According to the 24-hour chart, there is a support level at 9.87, which, if violated, would cause prices to drop to 9.64. In the upper region, resistance lies at 10.31. The next price resistance is at 10.52. RSI (Relative Strength Index) is 43.72 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.45, which suggests the price will decrease in the coming days. Percent R is at 83.82%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.
Is Amicus Therapeutics Inc. subject to short interest?
Stocks of Amicus Therapeutics Inc. saw a sharp steep in short interest on Jul 14, 2022 dropping by -8.18 million shares to 21.75 million. Data from Yahoo Finance shows that the short interest on Jun 14, 2022 was 29.93 million shares. A decline of -37.61% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 5.78 of the overall float, the days-to-cover ratio (short ratio) decline to 5.78.
Which companies own the most shares of Amicus Therapeutics Inc. (FOLD)?
According to Perceptive Advisors LLC filings, the company currently owns 26,895,532 shares, which is about 9.59% of the total FOLD shares outstanding. The investor’s shares have plunged by -660,313 from its previous 13-F filing of 27555845.0 shares. With the completion of the buy transaction, Avoro Capital Advisor LLC’s stake is now worth $279,792,000. The Vanguard Group, Inc. acquire a 0.29% interest valued at $261.6 million while Redmile Group LLC sold a -170,495 stake. A total of 671,648 shares of Amicus Therapeutics Inc. were sold by BlackRock Fund Advisors during the quarter, and 1,157,528 were bought by Janus Henderson Investors US LLC. In its current portfolio, Morgan Stanley & Co. LLC holds 14,936,557 shares valued at $155.94 million.
In terms of Amicus Therapeutics Inc. share price expectations, FactSet research, analysts set an average price target of $14.64 in the next 12 months, up nearly 40.14% from the previous closing price of $9.99. Analysts anticipate Amicus Therapeutics Inc. stock to reach $20.00 by 2022, with the lowest price target being $10.00. In spite of this, 13 analysts ranked Amicus Therapeutics Inc. stock as an Overweight at the end of 2022. On September 30, 2021, JP Morgan assigned a price target of “an Overweight” to the stock and upgraded coverage with a $16.